This discussion needs to be bumped.
You are correct. It is the elephant in the room that FDA must address.
Approving Jakafi which is the SOC on the basis of a single-arm trial, with lower efficacy and WAY MORE side effects.
Let's remind everyone what they are.
Compare this to Remestemcel-L which the FDA has acknowledged that there are NO safety issues.
Ruxolitinib vs Ryoncil, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |